<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004139</url>
  </required_header>
  <id_info>
    <org_study_id>CALGB-39809</org_study_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>CLB-39809</secondary_id>
    <secondary_id>CDR0000067369</secondary_id>
    <nct_id>NCT00004139</nct_id>
  </id_info>
  <brief_title>Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer</brief_title>
  <official_title>Phase II Randomized Trial of Gemcitabine/Docetaxel and Gemcitabine/Irinotecan in Stage IIIB/IV Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Phase II trial to compare the effectiveness of gemcitabine plus either docetaxel or
      irinotecan in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare the complete and overall response rate to gemcitabine and docetaxel
      versus gemcitabine and irinotecan in chemotherapy naive patients with stage IIIB or IV
      non-small cell lung cancer. II. Compare the overall and failure free survival, duration of
      response, and toxicity associated with these combination regimens in this patient population.

      OUTLINE: This is a randomized study. Patients are stratified according to disease stage
      (stage IIIB vs stage IV without CNS involvement vs stage IV with CNS involvement vs
      recurrent/progressive disease post surgery and/or radiotherapy). Patients are randomized to
      one of two treatment arms. Arm I: Patients receive gemcitabine IV over 30 minutes immediately
      followed by irinotecan IV over 90 minutes on days 1 and 8. Arm II: Patients receive
      gemcitabine IV over 30 minutes immediately followed by docetaxel IV over 60 minutes on days 1
      and 8. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable
      toxicity. Patients achieving partial or complete response or stable disease receive treatment
      for least 6 courses and for 2 additional courses beyond the maximum response, and then at the
      investigator's discretion. Patients are followed every 3 months for 1 year, every 6 months
      for 2 years, and then annually thereafter until disease progression or death.

      PROJECTED ACCRUAL: A total of 72 patients (36 per treatment arm) will be accrued for this
      study within 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1999</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>failure-free survival</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine + Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <arm_group_label>Gemcitabine + Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>Gemcitabine + Irinotecan</arm_group_label>
    <arm_group_label>Gemcitabine + Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>Gemcitabine + Irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically or cytologically confirmed stage IIIB, IV, or
        recurrent non-small cell lung cancer (NSCLC) including: Squamous cell carcinoma
        Adenocarcinoma (including bronchoalveolar cell) Large cell anaplastic carcinoma (including
        giant and clear cell carcinomas) Stage IIIB eligible for other CALGB protocols consisting
        of combined chemotherapy and chest radiotherapy not permitted Malignant pleural effusion
        allowed CNS metastases allowed following completion of cranial radiotherapy
        Unidimensionally or bidimensionally measurable disease Solid tumor mass or hilar lesion
        surrounded by aerated lung Pleural based mass Mediastinal or hilar adenopathy clearly
        measurable No bone only disease No pleural or pericardial effusions No irradiated lesions
        unless progression is documented following radiotherapy

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: Not
        specified Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least
        100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL SGOT no greater than 2 times upper
        limit of normal (ULN) Alkaline phosphatase less than 2.5 times ULN if SGOT is greater than
        1.5 times ULN Renal: Creatinine no greater than 2.0 mg/dL Other: No other malignancies
        within the past 5 years except curatively treated basal or squamous cell skin cancer or
        carcinoma in situ of the cervix or breast Not pregnant or nursing Fertile patients must use
        effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
        Characteristics No prior chemotherapy for NSCLC Endocrine therapy: Not specified
        Radiotherapy: See Disease Characteristics At least 2 weeks since prior radiotherapy At
        least 2 weeks since prior whole brain radiotherapy or stereotactic radiotherapy for CNS
        disease Surgery: At least 2 weeks since prior surgery for CNS disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caio Max S. Rocha Lima, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vincent T. Lombardi Cancer Research Center, Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Southern Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425-0721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Greenville</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee, Memphis Cancer Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rocha Lima CM, Rizvi NA, Zhang C, Herndon JE 2nd, Crawford J, Govindan R, King GW, Green MR; Cancer Leukemia Group B. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. Ann Oncol. 2004 Mar;15(3):410-8. Review.</citation>
    <PMID>14998842</PMID>
  </results_reference>
  <results_reference>
    <citation>Rocha Lima CM, Rizvi NA, Zhang K, et al.: CALGB 39809: Randomized phase II trial of gemcitabine/irinotecan and gemcitabine/docetaxel in stage IIIB (malignant pleural effusion) or stage IV NSCLC. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1344, 2002.</citation>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>May 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2004</study_first_posted>
  <last_update_submitted>July 19, 2016</last_update_submitted>
  <last_update_submitted_qc>July 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

